Soon after, large randomized adjuvant trials, including HERA, NSABP B-31, and NCCTG N9831, confirmed the benefit of adding trastuzumab to standard chemotherapy for one year in early-stage HER2-positive breast cancer, reducing recurrence and mortality rates substantially [5,6]. The gene discussed is ERBB2; the disease is breast cancer.